Exploiting DNA Repair - Stand Up To Cancer

Give Now

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  Exploiting DNA Repair

Pancreatic Cancer Collective Research Team:
Exploiting DNA-Repair Gene Mutations in Pancreatic Cancer New Therapies Challenge

Grant Terms
Round 1: November 2018–December 2019
Round 2: January 2020–December 2022

Drugs called PARP inhibitors are being used to treat ovarian cancer by interfering with the processes of cell division that allows tumors to grow. Based on preclinical work suggesting a combination of first-line therapy gemcitabine with other drugs that block cellular pathways also involved in DNA repair, the team is testing three combinations in clinical trials. It is hoped that together, these therapies will in many cases cause pancreatic tumors to shrink.

ABOUT THIS TEAM’S RESEARCH

Building on recent large-scale sequencing efforts demonstrating deficiencies in DNA repair in pancreatic cancer, the team is evaluating DNA repair inhibitors in pancreatic cancer. While clinical trials of therapy using PARP inhibitors alone have shown modest activity in pancreatic cancer, the team’s pre-clinical work suggests outcomes from PARP inhibitor monotherapy can be improved upon by combination treatment strategies involving DNA repair–targeted therapies and be effective in patients experiencing PARP inhibitor resistance.

To accomplish this goal, the researchers first studied three classes of DNA repair-targeted therapies-CHK1, ATR, and PARP inhibitors-as single agents in organoid cultures of patient-derived pancreatic cancer tumors. The team sought to identify the most promising combination of DNA repair–targeted therapies and performing drug testing using patient-derived mouse models of pancreatic cancer. Through the organoid and animal model drug sensitivity experiments, the molecular mechanisms of sensitivity and resistance were analyzed. A goal of these mechanistic studies is to develop biomarkers that can be used in clinical trials to pinpoint the pancreatic cancer patient population most likely to benefit from these therapies.

In round two, the team hopes to improve on the effect of PARP inhibitors through combination therapy for pancreatic cancer patients with DNA repair mutations, including patients whose pancreatic cancers both have and have not progressed on platinum-based chemotherapy regimens. Their preclinical data suggests that combining gemcitabine with inhibitors targeting regulatory proteins compensating for replicative stress could be effective. Therefore, the team is planning three clinical trials combining gemcitabine with either: 1) an ATR inhibitor, 2) a CHK1 inhibitors, or 3) a WEE1 inhibitor. The team plans to examine these different therapeutic strategies with the intention of identifying combinations for further clinical evaluation.

This team is part of the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation for Pancreatic Cancer Research and Stand Up To Cancer.

MEET THE TEAM

The top scientists and researchers on the Pancreatic Cancer Collective Research Team: Exploiting DNA-Repair Gene Mutations in Pancreatic Cancer New Therapies Challenge come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the Pancreatic Cancer Collective Research Team: Exploiting DNA-Repair Gene Mutations in Pancreatic Cancer New Therapies Challenge.

Research Team Members

Alan D. D’Andrea, MD
Dana-Farber Cancer Institute
Leader

James M. Cleary, MD, PhD
Dana-Farber Cancer Institute
Co-leader

Geoffrey I. Shapiro, MD, PhD
Dana-Farber Cancer Institute
Principal

Florence Freitas
Advocate

Donald Watson
Dana-Farber Cancer Institute
Project Manager

“We believe that DNA repair inhibitors will have particular utility in the treatment of pancreatic cancer. There may be as much as 20 or even 30% of those patients who will respond to these new drugs.”

Alan D. D'Andrea, MD
Dana-Farber Cancer Institute

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click on the link to see summaries of the research results so far for the Pancreatic Cancer Collective Research Team: Exploiting DNA-Repair Gene Mutations in Pancreatic Cancer New Therapies Challenge.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in November 2018; links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available, in fact the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials don’t get completed because not enough people participate.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.